Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Mind Medicine (MindMed) Inc.

Numinus Wellness Inc. provides solutions to develop and deliver psychedelic-assisted psychotherapy and transform the mental health landscape. The company operates in two divisions, Salvation Botanicals and Numinus Health. The Salvation Botanicals division offers laboratory services, such as cultivation, analytical testing, product research and development, and ancillary services in the area of psychedelics; and full suite testing and custom testing of cannabis. The Numinus Health division provides supportive therapies and technologies to heal, connect, and grow with a focus on treating mental health and substance abuse; and services for psychotherapy, counselling, neurofeedback, physiotherapy, and other therapies. This division also offers training, facilities, and other operational resources to practitioners. The company is headquartered in Vancouver, Canada.

Numinus Wellness Inc.

Awakn Life Sciences Corp., a biotechnology company, engages in the researching, developing, operations, and delivering of psychedelic therapeutics to treat addiction and other mental health conditions in the United Kingdom and Europe. The company is headquartered in Toronto, Canada.

Awakn Life Sciences Corp.

MindCure is a community service organization that provides enhanced care management and community support services, focusing on mental health and wellness. The organization connects individuals to essential resources and supports, trained caregivers, and custom action plans.

MindCure

Mind Medicine Inc is a biopharmaceutical company. The company produces to treat brain health disorders. The company discovers, develops, and deploys psychedelic inspired medicines and therapies to address addiction and mental illness. The company is assembling a compelling drug development pipeline of treatments based on psychedelic substances. The firm is having an approach towards developing the next generation of psychedelic-inspired medicines and therapies.

MindMed works to improve patient outcomes through a pipeline of novel drug candidates, focusing on the therapeutic potential of psychedelics and other compounds to address unmet needs in psychiatry, addiction, pain, and neurology.

Metric
Company Name	Mind Medicine (MindMed) Inc.	Numinus Wellness Inc.	Awakn Life Sciences Corp.	MindCure
Symbol	MNMD	NUMI	AWKN
MSH ID	CO:MINDMED	COM:NUMINUS	COM:AWAKNLIFESCIENCES	CARE:MINDCURE
Market	STOCKS	STOCKS	STOCKS	PRIVATE
Sector	Healthcare	Healthcare	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Medical - Care Facilities	Biotechnology	Mental Health Services
Country	CA	CA	CA	US
Stage	Post-IPO Equity
Employee Count	57	200	44	51
Website	mindmed.co	numinus.com	awaknlifesciences.com	mindcure.care
LinkedIn		numinus
Founders

Metric
Market Cap	500.56M	9.07M	3.14M
Enterprise Value
Monthly Web Traffic	17.91K
Web Traffic Growth	-0.36
Valuation
Raised Capital	75M

Metric
Revenue	16.40M	1.06M
Revenue (LTM)
Revenue (NTM)
Gross Profit	5.92M	-1.10M
EBITDA	-17.43M	-6.08M
Operating Income	-19.44M	-6.50M
Net Income	-21.40M	-6.47M
EPS	-0.08	-0.25
Diluted EPS	-0.08	-0.25
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.35	-0.81
Operating Profit Margin	-0.93	-6.37
EBITDA Margin	-1.06	-5.74
Net Profit Margin	-1.17	-6.41
Return on Equity	-1.49	13.52
Return on Assets	-1.40	-6.09
Return on Capital Employed	-1.54	6.96

CO:MINDMED

MindMed

Last Close

7.09

22/11 21:00

Market Cap

525.05M

Beta: -

Volume Today

1.02M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-1.07	-0.64
P/B Ratio	3.00	-4.51
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.04	4.28
EV Multiple	-0.27	-0.78

Metric
Days Sales Outstanding	35.49	120.95
Days Payables Outstanding	59.40
Days Inventory Outstanding	4.17	0.00
Operating Cycle	39.66	120.95
Cash Conversion Cycle	-13.85	-193.31
Asset Turnover	1.53	0.95

Metric
Operating Cash Flow	-16.10M	-5.21M
Free Cash Flow	-16.37M	-5.28M
Cash Flow to Debt	-2.80	4.69
Operating Cash Flow/Sales	-0.68	-7.31
Free Cash Flow Yield	-0.62	-1.42

Metric
Cash & Equivalents	6.07M	389.67K
Accounts Receivable	-937.23K	-10.98K
Inventory
Goodwill
Debt to Capitalization	0.40	0.63
Debt to Assets	0.35
Current Ratio	2.10	0.51
Quick Ratio	2.09	0.44

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.09	0.90
R&D to Revenue	0.03	0.90
SG&A to Revenue	1.23	3.41